Enovix Corporation (NASDAQ:ENVX) filed its quarterly report on Form 10-Q for the fiscal quarter ended July 5, 2026, with the U.S. Securities and Exchange Commission, disclosing condensed consolidated financial data as of that date.
Key Highlights
- Shares outstanding: As of August 7, 2026, 219,448,535 shares of common stock, par value $0.0001 per share, were issued and outstanding.
- Cash and cash equivalents: $33,741 thousand as of July 5, 2026, compared with $106,014 thousand as of December 28, 2025.
- Short-term investments: $442,040 thousand as of July 5, 2026, up from $406,026 thousand as of December 28, 2025.
- Accounts receivable, net: $3,097 thousand as of July 5, 2026, compared with $4,421 thousand as of December 28, 2025.
- Inventory: $17,520 thousand as of July 5, 2026, compared with $13,617 thousand as of December 28, 2025.
- Filer status: The company indicated it is classified as a large accelerated filer.
Enovix Balance Sheet Snapshot for Fiscal Quarter Ended July 5, 2026
Enovix Corporation filed its Form 10-Q for the fiscal quarter ended July 5, 2026, covering condensed consolidated financial statements, management's discussion and analysis, and other required disclosures. According to the filing, the company is incorporated in Delaware and headquartered at 3501 W Warren Avenue, Fremont, California 94538. Its common stock trades on The Nasdaq Global Select Market under the symbol ENVX.
The condensed consolidated balance sheet reported in the filing shows cash and cash equivalents of $33,741 thousand as of July 5, 2026, a decrease from $106,014 thousand as of December 28, 2025. The filing also reported short-term investments of $442,040 thousand at the end of the fiscal quarter, compared with $406,026 thousand at the prior fiscal year-end. Accounts receivable, net, stood at $3,097 thousand, while notes receivable, net, fell to zero from $4,012 thousand at December 28, 2025. Inventory increased to $17,520 thousand from $13,617 thousand over the same period.
The filing contains forward-looking statements relating to, among other items, manufacturing scale, product milestones, customer qualification timelines, and financial performance. According to the filing, these statements "involve a number of risks and uncertainties, some of which are beyond our control," and the company stated it "undertakes no obligation to update or revise any forward-looking statements" except as required by law. Risk factors are described in Part II, Item 1A of the quarterly report.
What Was Disclosed
Enovix filed a Form 10-Q for the fiscal quarter ended July 5, 2026, disclosing balance sheet data showing a decline in cash and an increase in short-term investments and inventory relative to December 28, 2025, along with 219,448,535 shares outstanding as of August 7, 2026.



Please wait processing your request...